JP2001504806A - 新規なアミノアルコール誘導体、それらの製造方法およびこれらの化合物を含有する薬剤および試薬 - Google Patents
新規なアミノアルコール誘導体、それらの製造方法およびこれらの化合物を含有する薬剤および試薬Info
- Publication number
- JP2001504806A JP2001504806A JP51324998A JP51324998A JP2001504806A JP 2001504806 A JP2001504806 A JP 2001504806A JP 51324998 A JP51324998 A JP 51324998A JP 51324998 A JP51324998 A JP 51324998A JP 2001504806 A JP2001504806 A JP 2001504806A
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- amino
- propyl
- group
- different
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims description 159
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 239000003814 drug Substances 0.000 title claims description 10
- 229940079593 drug Drugs 0.000 title claims description 4
- 238000000034 method Methods 0.000 title abstract description 27
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 6
- 150000001414 amino alcohols Chemical class 0.000 title abstract description 5
- -1 piperidinediyl Chemical group 0.000 claims abstract description 128
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 35
- 239000001257 hydrogen Substances 0.000 claims abstract description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 150000002429 hydrazines Chemical class 0.000 claims abstract description 11
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 8
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 8
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 7
- 229930195734 saturated hydrocarbon Natural products 0.000 claims abstract description 7
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims abstract description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 27
- 150000002148 esters Chemical class 0.000 claims description 15
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 238000001890 transfection Methods 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 230000008482 dysregulation Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 125000004494 ethyl ester group Chemical group 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000012096 transfection reagent Substances 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 230000002155 anti-virotic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 27
- 239000000126 substance Substances 0.000 abstract description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 99
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 50
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 239000007858 starting material Substances 0.000 description 25
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 22
- 238000001704 evaporation Methods 0.000 description 22
- 230000008020 evaporation Effects 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- LPWCRLGKYWVLHQ-UHFFFAOYSA-N tetradecanoyl chloride Chemical compound CCCCCCCCCCCCCC(Cl)=O LPWCRLGKYWVLHQ-UHFFFAOYSA-N 0.000 description 21
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 13
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 12
- NQGIJDNPUZEBRU-UHFFFAOYSA-N dodecanoyl chloride Chemical compound CCCCCCCCCCCC(Cl)=O NQGIJDNPUZEBRU-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- MLQBTMWHIOYKKC-KTKRTIGZSA-N (z)-octadec-9-enoyl chloride Chemical compound CCCCCCCC\C=C/CCCCCCCC(Cl)=O MLQBTMWHIOYKKC-KTKRTIGZSA-N 0.000 description 11
- IFABLCIRROMTAN-MDZDMXLPSA-N (e)-1-chlorooctadec-9-ene Chemical compound CCCCCCCC\C=C\CCCCCCCCCl IFABLCIRROMTAN-MDZDMXLPSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000005984 hydrogenation reaction Methods 0.000 description 8
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 8
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 5
- BZBNGMOEKRTOQX-UHFFFAOYSA-N 2-[[1-(3-aminopropyl)piperidin-4-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound NCCCN1CCC(N(CCO)CCO)CC1 BZBNGMOEKRTOQX-UHFFFAOYSA-N 0.000 description 5
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical class O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 229910052785 arsenic Inorganic materials 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- HGIAFZVBNUYSJA-UHFFFAOYSA-N 2-[2-hydroxyethyl-[(1-pyridin-4-ylpiperidin-4-yl)methyl]amino]ethanol Chemical compound C1CC(CN(CCO)CCO)CCN1C1=CC=NC=C1 HGIAFZVBNUYSJA-UHFFFAOYSA-N 0.000 description 4
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CPUWQTHLVONZJX-UHFFFAOYSA-N 2-[[1-[3-(dimethylamino)propyl]piperidin-4-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound CN(C)CCCN1CCC(N(CCO)CCO)CC1 CPUWQTHLVONZJX-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- XMHOMTGFKVOMPD-UHFFFAOYSA-N 2-[2-hydroxyethyl(piperidin-4-yl)amino]ethanol Chemical compound OCCN(CCO)C1CCNCC1 XMHOMTGFKVOMPD-UHFFFAOYSA-N 0.000 description 2
- YTBCZLCPUYEQGY-UHFFFAOYSA-N 2-[2-hydroxyethyl-(1-pyridin-4-ylpiperidin-4-yl)amino]ethanol Chemical compound C1CC(N(CCO)CCO)CCN1C1=CC=NC=C1 YTBCZLCPUYEQGY-UHFFFAOYSA-N 0.000 description 2
- JTEWFDIFCBAZQF-UHFFFAOYSA-N 2-[3-[3-(dimethylamino)propyl-methylamino]propyl-(2-hydroxyethyl)amino]ethanol Chemical compound CN(C)CCCN(C)CCCN(CCO)CCO JTEWFDIFCBAZQF-UHFFFAOYSA-N 0.000 description 2
- PTDYQIKOHJPNCD-UHFFFAOYSA-N 2-[3-[4-(3-aminopropylamino)piperidin-1-yl]propyl-(2-hydroxyethyl)amino]ethanol Chemical compound NCCCNC1CCN(CCCN(CCO)CCO)CC1 PTDYQIKOHJPNCD-UHFFFAOYSA-N 0.000 description 2
- KTMDLKWKAJTQTJ-UHFFFAOYSA-N 2-[[1-(3-aminopropyl)piperidin-4-yl]methyl-(2-hydroxyethyl)amino]ethanol Chemical compound NCCCN1CCC(CN(CCO)CCO)CC1 KTMDLKWKAJTQTJ-UHFFFAOYSA-N 0.000 description 2
- LZLFIXVMNGSODU-UHFFFAOYSA-N 2-[[1-[3-(dimethylamino)propyl]piperidin-4-yl]methyl-(2-hydroxyethyl)amino]ethanol Chemical compound CN(C)CCCN1CCC(CN(CCO)CCO)CC1 LZLFIXVMNGSODU-UHFFFAOYSA-N 0.000 description 2
- PXJBCMWIAPDWAU-UHFFFAOYSA-N 2-piperidin-4-ylethanamine Chemical compound NCCC1CCNCC1 PXJBCMWIAPDWAU-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 2
- CKOZVEHVVHCMGD-UHFFFAOYSA-N 5-[(4-fluorophenyl)methyl]-n,n-dimethyltetrazole-1-carboxamide Chemical compound CN(C)C(=O)N1N=NN=C1CC1=CC=C(F)C=C1 CKOZVEHVVHCMGD-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- YIQNPTXZBRNLMT-CLFAGFIQSA-N CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)C1CCN(CCN)CC1 Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)C1CCN(CCN)CC1 YIQNPTXZBRNLMT-CLFAGFIQSA-N 0.000 description 2
- PKZQONAFPVEWSZ-WRBBJXAJSA-N CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCCN1CCC(N(C)C)CC1 Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCCN1CCC(N(C)C)CC1 PKZQONAFPVEWSZ-WRBBJXAJSA-N 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- HKWLPLLFJNQXFJ-UHFFFAOYSA-N dodecanoyl bromide Chemical compound CCCCCCCCCCCC(Br)=O HKWLPLLFJNQXFJ-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- LTNZXZSHQGVQEB-UHFFFAOYSA-N n',n'-bis(3-dodecoxypropyl)ethane-1,2-diamine Chemical compound CCCCCCCCCCCCOCCCN(CCN)CCCOCCCCCCCCCCCC LTNZXZSHQGVQEB-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 229910001925 ruthenium oxide Inorganic materials 0.000 description 2
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 238000007738 vacuum evaporation Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RRQWVJIFKFIUJU-KTKRTIGZSA-N (z)-1-bromooctadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCBr RRQWVJIFKFIUJU-KTKRTIGZSA-N 0.000 description 1
- IFPMZBBHBZQTOV-UHFFFAOYSA-N 1,3,5-trinitro-2-(2,4,6-trinitrophenyl)-4-[2,4,6-trinitro-3-(2,4,6-trinitrophenyl)phenyl]benzene Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C=2C(=C(C=3C(=CC(=CC=3[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)C(=CC=2[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)=C1[N+]([O-])=O IFPMZBBHBZQTOV-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
- AUERUDPETOKUPT-UHFFFAOYSA-N 1-(3-chloropropyl)-4-methylpiperazine Chemical compound CN1CCN(CCCCl)CC1 AUERUDPETOKUPT-UHFFFAOYSA-N 0.000 description 1
- FXRGHUFVXAVXOA-UHFFFAOYSA-N 1-[4-[4-[bis(2-hydroxyethyl)amino]piperidin-1-yl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1N1CCC(N(CCO)CCO)CC1 FXRGHUFVXAVXOA-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- OWYCGXDTHHXUNY-UHFFFAOYSA-N 2-(8-benzyl-1-oxa-4,8-diazaspiro[4.5]decan-4-yl)ethanol Chemical compound OCCN1CCOC11CCN(CC=2C=CC=CC=2)CC1 OWYCGXDTHHXUNY-UHFFFAOYSA-N 0.000 description 1
- OQZZONWTDROODQ-UHFFFAOYSA-N 2-[2-(ethylamino)ethyl-(2-hydroxyethyl)amino]ethanol Chemical compound CCNCCN(CCO)CCO OQZZONWTDROODQ-UHFFFAOYSA-N 0.000 description 1
- CYOIAXUAIXVWMU-UHFFFAOYSA-N 2-[2-aminoethyl(2-hydroxyethyl)amino]ethanol Chemical compound NCCN(CCO)CCO CYOIAXUAIXVWMU-UHFFFAOYSA-N 0.000 description 1
- DITKEHYNDKIKDL-UHFFFAOYSA-N 2-[2-dodecanoyloxyethyl(2-piperidin-4-ylethyl)amino]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCCCCCC)CCC1CCNCC1 DITKEHYNDKIKDL-UHFFFAOYSA-N 0.000 description 1
- UPGURZIHJFDUEA-UHFFFAOYSA-N 2-[2-dodecanoyloxyethyl-[(1-pyridin-4-ylpiperidin-4-yl)methyl]amino]ethyl dodecanoate;hydrochloride Chemical compound Cl.C1CC(CN(CCOC(=O)CCCCCCCCCCC)CCOC(=O)CCCCCCCCCCC)CCN1C1=CC=NC=C1 UPGURZIHJFDUEA-UHFFFAOYSA-N 0.000 description 1
- MELFHTZZVUDEFU-UHFFFAOYSA-N 2-[2-dodecanoyloxyethyl-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]amino]ethyl dodecanoate Chemical compound C1CC(CCN(CCOC(=O)CCCCCCCCCCC)CCOC(=O)CCCCCCCCCCC)CCN1C1=CC=NC=C1 MELFHTZZVUDEFU-UHFFFAOYSA-N 0.000 description 1
- HAYQENVFBIFONO-UHFFFAOYSA-N 2-[2-dodecanoyloxyethyl-[3-[(1-pyridin-4-ylpiperidin-4-yl)amino]propyl]amino]ethyl dodecanoate Chemical compound C1CC(NCCCN(CCOC(=O)CCCCCCCCCCC)CCOC(=O)CCCCCCCCCCC)CCN1C1=CC=NC=C1 HAYQENVFBIFONO-UHFFFAOYSA-N 0.000 description 1
- GASRNOIHUYRROF-UHFFFAOYSA-N 2-[2-hydroxyethyl(2-pyridin-4-ylethyl)amino]ethanol Chemical compound OCCN(CCO)CCC1=CC=NC=C1 GASRNOIHUYRROF-UHFFFAOYSA-N 0.000 description 1
- CFABNGFSTWIYEQ-UHFFFAOYSA-N 2-[2-hydroxyethyl(3-piperidin-1-ylpropyl)amino]ethanol Chemical compound OCCN(CCO)CCCN1CCCCC1 CFABNGFSTWIYEQ-UHFFFAOYSA-N 0.000 description 1
- XKKOYRXZPYUZEV-UHFFFAOYSA-N 2-[2-hydroxyethyl(piperidin-4-ylmethyl)amino]ethanol Chemical compound OCCN(CCO)CC1CCNCC1 XKKOYRXZPYUZEV-UHFFFAOYSA-N 0.000 description 1
- SGQQYKYAEOYEPU-UHFFFAOYSA-N 2-[2-hydroxyethyl-[3-(4-methylpiperazin-1-yl)propyl]amino]ethanol Chemical compound CN1CCN(CCCN(CCO)CCO)CC1 SGQQYKYAEOYEPU-UHFFFAOYSA-N 0.000 description 1
- SOYIRZJNXZDJDW-UHFFFAOYSA-N 2-[2-hydroxyethyl-[3-[(1-pyridin-4-ylpiperidin-4-yl)amino]propyl]amino]ethanol Chemical compound C1CC(NCCCN(CCO)CCO)CCN1C1=CC=NC=C1 SOYIRZJNXZDJDW-UHFFFAOYSA-N 0.000 description 1
- ZFYZBHZYICUOIH-UHFFFAOYSA-N 2-[3-(3-aminopropylamino)propyl-(2-dodecanoyloxyethyl)amino]ethyl dodecanoate;hydrochloride Chemical compound Cl.CCCCCCCCCCCC(=O)OCCN(CCCNCCCN)CCOC(=O)CCCCCCCCCCC ZFYZBHZYICUOIH-UHFFFAOYSA-N 0.000 description 1
- BGTXWAPTPBXAJE-UHFFFAOYSA-N 2-[3-(4-aminobutylamino)propyl-(2-dodecanoyloxyethyl)amino]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCN(CCCNCCCCN)CCOC(=O)CCCCCCCCCCC BGTXWAPTPBXAJE-UHFFFAOYSA-N 0.000 description 1
- OTHBKBMSXJYJKC-UHFFFAOYSA-N 2-[3-(diethylamino)propyl-(2-dodecanoyloxyethyl)amino]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCN(CCCN(CC)CC)CCOC(=O)CCCCCCCCCCC OTHBKBMSXJYJKC-UHFFFAOYSA-N 0.000 description 1
- AVPZOPSERZUXBU-UHFFFAOYSA-N 2-[3-(diethylamino)propyl-(2-tetradecanoyloxyethyl)amino]ethyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCN(CCCN(CC)CC)CCOC(=O)CCCCCCCCCCCCC AVPZOPSERZUXBU-UHFFFAOYSA-N 0.000 description 1
- BLLZOROPAPOMSO-UHFFFAOYSA-N 2-[3-(dimethylamino)propyl-(2-dodecanoyloxyethyl)amino]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCN(CCCN(C)C)CCOC(=O)CCCCCCCCCCC BLLZOROPAPOMSO-UHFFFAOYSA-N 0.000 description 1
- PSLKPIPXUIYIGT-UHFFFAOYSA-N 2-[3-(dimethylamino)propyl-(2-tetradecanoyloxyethyl)amino]ethyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCN(CCCN(C)C)CCOC(=O)CCCCCCCCCCCCC PSLKPIPXUIYIGT-UHFFFAOYSA-N 0.000 description 1
- HCICNEYBZJZBCI-UHFFFAOYSA-N 2-[3-[3-(diethylamino)propyl-methylamino]propyl-(2-hydroxyethyl)amino]ethanol Chemical compound CCN(CC)CCCN(C)CCCN(CCO)CCO HCICNEYBZJZBCI-UHFFFAOYSA-N 0.000 description 1
- KJFYDKCUDGJNGU-UHFFFAOYSA-N 2-[3-[4-(2-aminoethyl)piperidin-1-yl]propyl-(2-hydroxyethyl)amino]ethanol Chemical compound NCCC1CCN(CCCN(CCO)CCO)CC1 KJFYDKCUDGJNGU-UHFFFAOYSA-N 0.000 description 1
- IWUNICDVAJBYLX-UHFFFAOYSA-N 2-[3-[4-(2-aminoethyl)piperidin-1-yl]propyl-(2-tetradecanoyloxyethyl)amino]ethyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCCCCCCCC)CCCN1CCC(CCN)CC1 IWUNICDVAJBYLX-UHFFFAOYSA-N 0.000 description 1
- NJXTXRUGYPWDNZ-UHFFFAOYSA-N 2-[3-[4-(aminomethyl)piperidin-1-yl]propyl-(2-tetradecanoyloxyethyl)amino]ethyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCCCCCCCC)CCCN1CCC(CN)CC1 NJXTXRUGYPWDNZ-UHFFFAOYSA-N 0.000 description 1
- NTNRFQUAXCKKJR-UHFFFAOYSA-N 2-[3-chloropropyl(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCCCl NTNRFQUAXCKKJR-UHFFFAOYSA-N 0.000 description 1
- LHLHHIJRDANQSZ-UHFFFAOYSA-N 2-[4-(3-aminopropylamino)butyl-(2-dodecanoyloxyethyl)amino]ethyl dodecanoate;hydrochloride Chemical compound Cl.CCCCCCCCCCCC(=O)OCCN(CCCCNCCCN)CCOC(=O)CCCCCCCCCCC LHLHHIJRDANQSZ-UHFFFAOYSA-N 0.000 description 1
- GSCUXTICYWCTQP-UHFFFAOYSA-N 2-[4-aminobutyl(2-hydroxyethyl)amino]ethanol Chemical compound NCCCCN(CCO)CCO GSCUXTICYWCTQP-UHFFFAOYSA-N 0.000 description 1
- FXAVWZJZNPPRGH-UHFFFAOYSA-N 2-[[1-(1-ethylpiperidin-4-yl)piperidin-4-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound C1CN(CC)CCC1N1CCC(N(CCO)CCO)CC1 FXAVWZJZNPPRGH-UHFFFAOYSA-N 0.000 description 1
- KWQCSQRJJAVRAI-UHFFFAOYSA-N 2-[[1-(2-aminoethyl)piperidin-4-yl]-(2-dodecanoyloxyethyl)amino]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCCCCCC)C1CCN(CCN)CC1 KWQCSQRJJAVRAI-UHFFFAOYSA-N 0.000 description 1
- RCJKIPTYDXHJIU-UHFFFAOYSA-N 2-[[1-(2-aminoethyl)piperidin-4-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound NCCN1CCC(N(CCO)CCO)CC1 RCJKIPTYDXHJIU-UHFFFAOYSA-N 0.000 description 1
- YEBDOILFRIQEKF-UHFFFAOYSA-N 2-[[1-(2-aminoethyl)piperidin-4-yl]methyl-(2-hydroxyethyl)amino]ethanol Chemical compound NCCN1CCC(CN(CCO)CCO)CC1 YEBDOILFRIQEKF-UHFFFAOYSA-N 0.000 description 1
- OQKZBAGXRNNCTG-UHFFFAOYSA-N 2-[[1-(3-aminopropyl)piperidin-4-yl]-(2-dodecanoyloxyethyl)amino]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCCCCCC)C1CCN(CCCN)CC1 OQKZBAGXRNNCTG-UHFFFAOYSA-N 0.000 description 1
- GNEAMAZFSDHRLO-UHFFFAOYSA-N 2-[[1-(4-aminobutyl)piperidin-4-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound NCCCCN1CCC(N(CCO)CCO)CC1 GNEAMAZFSDHRLO-UHFFFAOYSA-N 0.000 description 1
- NJUBWZLRFAWOBR-UHFFFAOYSA-N 2-[[1-(4-aminobutyl)piperidin-4-yl]methyl-(2-hydroxyethyl)amino]ethanol Chemical compound NCCCCN1CCC(CN(CCO)CCO)CC1 NJUBWZLRFAWOBR-UHFFFAOYSA-N 0.000 description 1
- ZBTUHYVDAJGWCA-UHFFFAOYSA-N 2-[[1-[4-(dimethylamino)butyl]piperidin-4-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound CN(C)CCCCN1CCC(N(CCO)CCO)CC1 ZBTUHYVDAJGWCA-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- IDLHTECVNDEOIY-UHFFFAOYSA-N 2-pyridin-4-ylethanamine Chemical compound NCCC1=CC=NC=C1 IDLHTECVNDEOIY-UHFFFAOYSA-N 0.000 description 1
- MFMWJOLWKUPCDB-UHFFFAOYSA-N 3-[4-[bis(2-hydroxyethyl)amino]piperidin-1-yl]propanenitrile Chemical compound OCCN(CCO)C1CCN(CCC#N)CC1 MFMWJOLWKUPCDB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GMUOKLWAXDEZGA-UHFFFAOYSA-N 4-(2-aminoethyl)piperidin-2-one Chemical compound NCCC1CCNC(=O)C1 GMUOKLWAXDEZGA-UHFFFAOYSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- ACOXURKIHJSMAC-UHFFFAOYSA-N 4-piperidin-1-ylbutan-1-amine Chemical compound NCCCCN1CCCCC1 ACOXURKIHJSMAC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- CIHPXHIRPSMBDK-AUYXYSRISA-N C1CC(N(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCN1C1CCN(C)CC1 Chemical compound C1CC(N(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCN1C1CCN(C)CC1 CIHPXHIRPSMBDK-AUYXYSRISA-N 0.000 description 1
- XGPCPKDXZWIKTB-WRBBJXAJSA-N C1CC(N(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCN1C1CCN(CC)CC1 Chemical compound C1CC(N(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCN1C1CCN(CC)CC1 XGPCPKDXZWIKTB-WRBBJXAJSA-N 0.000 description 1
- MAKWHVHGHMOXQN-CLFAGFIQSA-N C1CC(NCCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCN1C1=CC=NC=C1 Chemical compound C1CC(NCCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCN1C1=CC=NC=C1 MAKWHVHGHMOXQN-CLFAGFIQSA-N 0.000 description 1
- GDSWUVCEXAQLSI-WRBBJXAJSA-N CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)C1CCN(CCCN(C)C)CC1 Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)C1CCN(CCCN(C)C)CC1 GDSWUVCEXAQLSI-WRBBJXAJSA-N 0.000 description 1
- KRWYOPKHPDRKQE-CLFAGFIQSA-N CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)C1CCN(CCCN)CC1 Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)C1CCN(CCCN)CC1 KRWYOPKHPDRKQE-CLFAGFIQSA-N 0.000 description 1
- GAEZAUOFHGSNSO-CLFAGFIQSA-N CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CC1CCN(CCN)CC1 Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CC1CCN(CCN)CC1 GAEZAUOFHGSNSO-CLFAGFIQSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- YHMPPNKRDNNVIA-UHFFFAOYSA-N Cl.C(CCCCCCCCCCC)(=O)OCCN(CCOC(CCCCCCCCCCC)=O)CCCN1CCN(CC1)C Chemical compound Cl.C(CCCCCCCCCCC)(=O)OCCN(CCOC(CCCCCCCCCCC)=O)CCCN1CCN(CC1)C YHMPPNKRDNNVIA-UHFFFAOYSA-N 0.000 description 1
- CEQAKONVYRLWBF-AWLASTDMSA-N Cl.C1CC(CN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCN1C1=CC=NC=C1 Chemical compound Cl.C1CC(CN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCN1C1=CC=NC=C1 CEQAKONVYRLWBF-AWLASTDMSA-N 0.000 description 1
- JORJRNKXGPVSDX-ZVDJXTMWSA-N Cl.CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCN(CC)CC)CCOC(=O)CCCCCCC\C=C/CCCCCCCC Chemical compound Cl.CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCN(CC)CC)CCOC(=O)CCCCCCC\C=C/CCCCCCCC JORJRNKXGPVSDX-ZVDJXTMWSA-N 0.000 description 1
- KHXHDAQFSGDGPD-AWLASTDMSA-N Cl.CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCC1CCNCC1 Chemical compound Cl.CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCC1CCNCC1 KHXHDAQFSGDGPD-AWLASTDMSA-N 0.000 description 1
- QNMXDAPYJUOROQ-YIQDKWKASA-N Cl.CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCCN1CCN(C)CC1 Chemical compound Cl.CCCCCCCC\C=C/CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCCN1CCN(C)CC1 QNMXDAPYJUOROQ-YIQDKWKASA-N 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- PBKSQZGGFMXGAP-UHFFFAOYSA-N NC1(CCNCC1)CCCCN(CCOC(CCCCCCCCCCC)=O)CCOC(CCCCCCCCCCC)=O Chemical compound NC1(CCNCC1)CCCCN(CCOC(CCCCCCCCCCC)=O)CCOC(CCCCCCCCCCC)=O PBKSQZGGFMXGAP-UHFFFAOYSA-N 0.000 description 1
- SNGJBVNAAJBSPR-CLFAGFIQSA-N NC1(CCNCC1)CCCCN(CCOC(CCCCCCC\C=C/CCCCCCCC)=O)CCOC(CCCCCCC\C=C/CCCCCCCC)=O Chemical compound NC1(CCNCC1)CCCCN(CCOC(CCCCCCC\C=C/CCCCCCCC)=O)CCOC(CCCCCCC\C=C/CCCCCCCC)=O SNGJBVNAAJBSPR-CLFAGFIQSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 241000051616 Ulmus minor Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- XFHZJRXOUJFTOJ-UHFFFAOYSA-N [4-[[bis(2-hydroxyethyl)amino]methyl]piperidin-1-yl]-phenylmethanone Chemical compound C1CC(CN(CCO)CCO)CCN1C(=O)C1=CC=CC=C1 XFHZJRXOUJFTOJ-UHFFFAOYSA-N 0.000 description 1
- ROZSPJBPUVWBHW-UHFFFAOYSA-N [Ru]=O Chemical class [Ru]=O ROZSPJBPUVWBHW-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- IPIVAXLHTVNRBS-UHFFFAOYSA-N decanoyl chloride Chemical compound CCCCCCCCCC(Cl)=O IPIVAXLHTVNRBS-UHFFFAOYSA-N 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000492 nasalseptum Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- LTEKQAPRXFBRNN-UHFFFAOYSA-N piperidin-4-ylmethanamine Chemical compound NCC1CCNCC1 LTEKQAPRXFBRNN-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- PYLHQFUYUMDOMF-UHFFFAOYSA-N tetradecanoyl bromide Chemical compound CCCCCCCCCCCCCC(Br)=O PYLHQFUYUMDOMF-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下記式I: 〔式中、 Aは水素、基NR1R2、基NR1(CH2)pNR3R4、基(C=NH)NH2ま たはピリジニル残基であり、 BおよびDは同一であるか、あるいは異なり、各々は結合、C1〜C6アルキレ ン基または基NR5−C2〜C6−アルキレンであり、 Cはピペリジンジイルまたはピペラジンジイルであり、 WおよびXは同一であるか、あるいは異なり、各々は結合またはカルボニル基 であり、 YおよびZは同一であるか、あるいは異なり、各々は7〜24個の炭素原子を 有する飽和もしくは不飽和の炭化水素基であり、 R1〜R5は同一であるか、あるいは異なり、各々は水素またはC1〜C6アルキ ル基であり、 mは整数0、1または2であり、そしてmが2である場合、双方の基Cは同一 であるか、あるいは異なることができ、 nおよびoは同一であるか、あるいは異なり、各々は整数2、3または4であ り、そしてpは整数2〜6である〕 の化合物ならびにそれらの生理学的に許容される塩の少なくとも1つを含有す る医薬製剤 ただしヒドラジン誘導体は含まれず、そしてAが水素または基(C=NH)N H2でありかつBおよびDが同一であるか、あるいは 異なり、結合またはアルキレン基である場合、mは0であることができない。 2.下記式I:〔式中、 Aは水素、基NR1R2、基NR1(CH2)pNR3R4、基(C=NH)NH2ま たはピリジニル残基であり、 BおよびDは同一であるか、あるいは異なり、各々は結合、C1〜C6アルキレ ン基または基NR5−C2〜C6−アルキレンであり、 Cはピペリジンジイルまたはピペラジンジイルであり、 WおよびXは同一であるか、あるいは異なり、各々は結合またはカルボニル基 であり、 YおよびZは同一であるか、あるいは異なり、各々は7〜24個の炭素原子を 有する飽和もしくは不飽和の炭化水素基であり、 R1〜R5は同一であるか、あるいは異なり、各々は水素またはC1〜C6アルキ ル基であり、 mは整数0、1または2であり、そしてmが2である場合、双方の残基Cは同 一であるか、あるいは異なることができ、 nおよびoは同一であるか、あるいは異なり、各々は整数2、3または4であ り、そして pは整数2〜6である〕 の化合物ならびにそれらの生理学的に許容される塩 ただしヒドラジン誘導体は含まれず、そしてAが水素または基(C=NH)N H2でありかつBおよびDが同一であるか、あるいは 異なり、結合またはアルキレン基である場合、mは0であることができず、そし てそれらは下記の化合物を含まない: オクタデカン酸−[(3−ジエチルアミノ−プロピル)イミノ]ビス(メチル− 2,1−エタンジイル)−エステル−塩酸塩、 オクタデカン酸−[(3−ジメチルアミノ−プロピル)イミノ]ジ−3,1−プ ロパンジイルエステル−二塩酸塩、 オクタデカン酸−[(3−ジメチルアミノ−プロピル)イミノ]ジ−3,1−プ ロパンジイルエステル、 オクタデカン酸−[(3−ジメチルアミノ−プロピル)イミノ]ジ−2,1−エ タンジイルエステル−塩酸塩、 ドコサン酸−2−[(3−ジメチルアミノ−プロピル)−[2−[(1−オキソ デシル)オキシ]エチル]アミノ]エチルエステル、 ヘキサデカン酸−[[2−(エチルメチルアミノ)エチル]イミノ]ジ−2,1 −エタンジイルエステル、 オクタデカン酸−[[3−(ジメチルアミノ)プロピル]イミノ]ジ−2,1− エタンジイルエステル、 オクタデカン酸−[[3−(ジメチルアミノ)プロピル]イミノ]ジ−2,1− エタンジイルエステル−二塩酸塩、 オクタデカン酸−[[3−(ジメチルアミノ)プロピル]イミノ]ジ−2,1− エタンジイルエステル、 N,N−ビス[3−(ドデシルオキシ)プロピル]−1,2−エタンジアミン、 オクタデカン酸−[[2−[(2−アミノエチル)アミノ]エチル]イミノ]ジ −2,1−エタンジイルエステル、 ステアリン酸−イミノビス−(エチレンイミノエチレン)−エステル−モノアセ テート。 3.WおよびXがCOである、請求項1〜2のいずれか一項に記 載の化合物。 4.YがC13H27又はC17H33である、請求項1〜3のいずれか一項に記載の 化合物。 5.ZがC13H27又はC17H33である、請求項1〜4のいずれか一項に記載の 化合物。 6.次の式II:(式中、A、B、C、D、nおよびoは請求項1に記載の意味を有し、ただしヒ ドラジン誘導体は含まれず、そしてAが水素または基(C=NH)NH2であり かつBおよびDが同一であるか、あるいは異なり、結合またはアルキレン残基で ある場合、mは0であることができない。) の化合物。 7.AがNH2またはN(CH3)2である、請求項1〜6のいずれか一項に記 載の化合物。 8.BおよびDが同一であるか、あるいは異なり、結合、C1〜C3−アルキレ ン残基であるか、あるいはmが0である場合、N(CH3)C3〜C4−アルキレン 残基である、請求項1〜7のいずれか一項に記載の化合物。 9.Cがピペリジンジイルである、請求項1〜8のいずれか一項に記載の化合 物。 10.mが0または1である、請求項1〜9のいずれか一項に記載の化合物。 11.nおよびoが2である、請求項1〜10のいずれか一項に記載の化合物 。 12.核酸をさらに含有する、請求項1、3〜5、7〜11のいずれか一項に 記載の化合物。 13.治療剤をさらに含有する、請求項1、3〜5、7〜11のいずれか一項 に記載の化合物。 14.治療剤を含有する遺伝子のフェリーおよびトランスフェクションのベヒ クルの生産のための、式I:〔式中、A、B、C、D、m、nおよびoは請求項1〜11に記載の意味を有し 、ただしヒドラジン誘導体は含まれず、そしてAが水素または基(C=NH)N H2でありかつBおよびDが同一であるか、あるいは異なり、結合またはアルキ レン残基である場合、mは0であることができない〕 の化合物の使用。 15.遺伝子治療のための医薬組成物を製造するための、請求項1〜12のい ずれか一項に記載の化合物の使用。 16.in vitroトランスフェクションのための請求項1〜13のいず れか一項に記載の化合物の使用。 17.in vitroトランスフェクション試薬の製造のための請求項1〜 13のいずれか一項に記載の化合物の使用。 18.癌の治療、抗ウイルスの治療、感染の治療、および調節異常により引き 起こされる疾患における薬剤の組合わせの製造のための請求項1〜13のいずれ か一項に記載の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19637043A DE19637043A1 (de) | 1996-09-12 | 1996-09-12 | Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien |
DE19637043.4 | 1996-09-12 | ||
PCT/EP1997/004944 WO1998011082A1 (de) | 1996-09-12 | 1997-09-10 | Neue aminoalkoholderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel und reagenzien |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001504806A true JP2001504806A (ja) | 2001-04-10 |
JP4191251B2 JP4191251B2 (ja) | 2008-12-03 |
Family
ID=7805345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51324998A Expired - Fee Related JP4191251B2 (ja) | 1996-09-12 | 1997-09-10 | 新規なアミノアルコール誘導体、それらの製造方法およびこれらの化合物を含有する薬剤および試薬 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0927174B1 (ja) |
JP (1) | JP4191251B2 (ja) |
KR (1) | KR20000036063A (ja) |
CN (1) | CN1087293C (ja) |
AT (1) | ATE380798T1 (ja) |
AU (1) | AU741636B2 (ja) |
BR (1) | BR9712818A (ja) |
CA (1) | CA2265765A1 (ja) |
DE (2) | DE19637043A1 (ja) |
TR (1) | TR199901200T2 (ja) |
WO (1) | WO1998011082A1 (ja) |
ZA (1) | ZA978170B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012515763A (ja) * | 2009-01-26 | 2012-07-12 | イスラエル インスティトゥート フォー バイオロジカル リサーチ | 複素二環スピロ化合物 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0108876D0 (en) * | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
CA2990668A1 (en) | 2015-06-24 | 2016-12-29 | Wenbin Ying | Ionizable compounds and compositions and uses therefof |
US10800635B2 (en) | 2017-08-30 | 2020-10-13 | Otis Elevator Company | Elevator door wedge monitoring system |
IL297084A (en) * | 2020-04-09 | 2022-12-01 | Suzhou Abogen Biosciences Co Ltd | Lipid nanoparticle compounds |
EP4132576A1 (en) | 2020-04-09 | 2023-02-15 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
CN115947672B (zh) * | 2023-01-04 | 2024-02-27 | 成都威斯津生物医药科技有限公司 | 用于递送药物的化合物、脂质体及药物载体 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3689494A (en) * | 1971-03-31 | 1972-09-05 | William R J Simpson | N-pyridinealkyl-alkanolamine nitrates |
US4158093A (en) * | 1977-12-15 | 1979-06-12 | Reilly Tar & Chemical Corporation | Process for substituting and dequaternizing pyridylethyl quaternary salts of pyridine and bypyridine bases |
JPS6325654A (ja) * | 1986-07-18 | 1988-02-03 | Fuji Photo Film Co Ltd | カラ−写真現像液組成物及びハロゲン化銀カラ−写真感光材料の処理方法 |
JPH05232660A (ja) * | 1992-02-19 | 1993-09-10 | Konica Corp | ハロゲン化銀カラー写真感光材料の処理方法 |
JP2588339B2 (ja) * | 1992-06-02 | 1997-03-05 | 花王株式会社 | 新規ジアミノジエステル及びその製造法 |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
JPH06340598A (ja) * | 1993-05-28 | 1994-12-13 | Lion Corp | 新規なジエステルジアミン化合物、その中間体及びその製造方法と柔軟剤 |
US5491263A (en) * | 1993-12-21 | 1996-02-13 | The Dow Chemical Company | Aminoethylation process for production of substituted ethylene diamines |
FR2717694B1 (fr) * | 1994-03-22 | 1996-05-03 | Seppic Sa | Une composition comprenant un plasmide recombinant et ses utilisations comme vaccin et médicament. |
FR2727679B1 (fr) * | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
US5635487A (en) * | 1994-12-29 | 1997-06-03 | Wolff; Jon A. | Amphipathic, micellar delivery systems for biologically active polyions |
DE19521412A1 (de) * | 1995-06-14 | 1996-12-19 | Boehringer Mannheim Gmbh | Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung |
-
1996
- 1996-09-12 DE DE19637043A patent/DE19637043A1/de not_active Withdrawn
-
1997
- 1997-09-10 CA CA002265765A patent/CA2265765A1/en not_active Abandoned
- 1997-09-10 AT AT97942012T patent/ATE380798T1/de not_active IP Right Cessation
- 1997-09-10 WO PCT/EP1997/004944 patent/WO1998011082A1/de active IP Right Grant
- 1997-09-10 BR BR9712818-0A patent/BR9712818A/pt unknown
- 1997-09-10 CN CN97199651A patent/CN1087293C/zh not_active Expired - Fee Related
- 1997-09-10 AU AU43841/97A patent/AU741636B2/en not_active Ceased
- 1997-09-10 TR TR1999/01200T patent/TR199901200T2/xx unknown
- 1997-09-10 EP EP97942012A patent/EP0927174B1/de not_active Expired - Lifetime
- 1997-09-10 DE DE59712902T patent/DE59712902D1/de not_active Expired - Lifetime
- 1997-09-10 JP JP51324998A patent/JP4191251B2/ja not_active Expired - Fee Related
- 1997-09-10 KR KR1019997002068A patent/KR20000036063A/ko not_active Application Discontinuation
- 1997-09-11 ZA ZA978170A patent/ZA978170B/xx unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012515763A (ja) * | 2009-01-26 | 2012-07-12 | イスラエル インスティトゥート フォー バイオロジカル リサーチ | 複素二環スピロ化合物 |
JP2015172098A (ja) * | 2009-01-26 | 2015-10-01 | イスラエル インスティトゥート フォー バイオロジカル リサーチ | 複素二環スピロ化合物又はその薬学的に許容される塩、これらの化合物を含む医薬組成物、および哺乳類のアルツハイマー病及びインスリン抵抗性症候群及び2型糖尿病を治療するための薬剤の調整における、これらの化合物の利用 |
Also Published As
Publication number | Publication date |
---|---|
EP0927174B1 (de) | 2007-12-12 |
AU741636B2 (en) | 2001-12-06 |
EP0927174A1 (de) | 1999-07-07 |
KR20000036063A (ko) | 2000-06-26 |
ATE380798T1 (de) | 2007-12-15 |
DE59712902D1 (de) | 2008-01-24 |
BR9712818A (pt) | 1999-12-21 |
CN1237161A (zh) | 1999-12-01 |
DE19637043A1 (de) | 1998-03-19 |
JP4191251B2 (ja) | 2008-12-03 |
CA2265765A1 (en) | 1998-03-19 |
AU4384197A (en) | 1998-04-02 |
WO1998011082A1 (de) | 1998-03-19 |
CN1087293C (zh) | 2002-07-10 |
ZA978170B (en) | 1999-03-11 |
TR199901200T2 (xx) | 1999-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6288234B1 (en) | Multibinding inhibitors of microsomal triglyceride transferase protein | |
KR101424989B1 (ko) | 벤조디아제핀 브로모도메인 억제제 | |
JP3210019B2 (ja) | カチオン性脂質 | |
US6355805B1 (en) | β3-adrenergic receptor agonists | |
JP5840763B2 (ja) | ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体 | |
JP6059723B2 (ja) | 4−(8−メトキシ−1−((1−メトキシプロパン−2−イル)−2−(テトラヒドロ−2H−ピラン−4−イル)−1H−イミダゾ[4,5−c]キノリン−7−イル)−3,5−ジメチルイソオキサゾールおよびブロモドメイン阻害剤としてのその使用 | |
AU692439B2 (en) | Heterocyclic compounds as platelet aggregation inhibitors | |
TWI272264B (en) | Glucocorticoid receptor modulators | |
US20090306134A1 (en) | Muscarinic receptor antagonists | |
EA004263B1 (ru) | АГОНИСТЫ β2-АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
JP2011201891A (ja) | 核酸のトランスフェクションのための新規脂質 | |
JP2019508475A (ja) | 化合物(s)−4−((s)−3−フルオロ−3−(2−(5,6,7,8−テトラヒドロ−1,8−ナフチリジン−2−イル)エチル)ピロリジン−1−イル)−3−(3−(2−メトキシエトキシ)フェニル)ブタン酸のクエン酸塩 | |
JP2008543820A (ja) | N−(2,2−ジメチルプロピル)−6−(3−フルオロ−5−((3−イソオキサゾリルアミノ)カルボニル)−2−メチルフェニル)−3−ピリジンカルボキサミド | |
JP2001504806A (ja) | 新規なアミノアルコール誘導体、それらの製造方法およびこれらの化合物を含有する薬剤および試薬 | |
TWI225856B (en) | Amide compounds | |
US6420560B1 (en) | H1—histamine receptor antagonists | |
US7097854B2 (en) | Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds | |
JP2002530364A (ja) | 両親媒性ポリアミン化合物 | |
MXPA99002386A (es) | Nuevos derivados de aminoalcohol, procedimiento para su preparacion y medicamentos y reactivos quecontienen esos compuestos | |
US20020128231A1 (en) | Aryl-indane compounds | |
JP2002517440A (ja) | 新規カルシウムチャンネル薬物および用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040910 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050223 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20070712 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080304 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080325 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080625 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080819 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080918 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110926 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |